Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI–IM–MS/MS Assay

The third-generation tyrosine kinase inhibitor (TKI), osimertinib, has revolutionized the treatment of patients with non-small cell lung carcinoma with epidermal growth factor receptor (EGFR)-activating mutation, and resistant to first- and second-generation TKIs. Osimertinib is now also proposed as...

Descripción completa

Detalles Bibliográficos
Autores principales: Fresnais, Margaux, Roth, André, Foerster, Kathrin I., Jäger, Dirk, Pfister, Stefan M., Haefeli, Walter E., Burhenne, Jürgen, Longuespée, Rémi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409122/
https://www.ncbi.nlm.nih.gov/pubmed/32674434
http://dx.doi.org/10.3390/cancers12071897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409122/
https://www.ncbi.nlm.nih.gov/pubmed/32674434
http://dx.doi.org/10.3390/cancers12071897

Ejemplares similares